Effect of neurokinin-1-receptor blockage on fracture healing in rats.
Animals
Collagen Type I
/ genetics
Collagen Type II
/ genetics
Disease Models, Animal
Femoral Fractures
/ drug therapy
Fracture Healing
/ drug effects
Gene Expression Regulation, Neoplastic
/ drug effects
Male
Neurokinin-1 Receptor Antagonists
/ administration & dosage
Osteocalcin
/ genetics
Piperidines
/ administration & dosage
Quinuclidines
/ administration & dosage
Rats
Rats, Sprague-Dawley
Substance P
/ administration & dosage
Treatment Outcome
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 07 2019
05 07 2019
Historique:
received:
29
01
2019
accepted:
12
06
2019
entrez:
7
7
2019
pubmed:
7
7
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Neurologic injury and selective blockage of sensory nerve endings is associated with impaired fracture healing, however, the role of specific neurotransmitters has not been sufficiently investigated. Our aim was to investigate the impact of specific Substance P-receptor blockage on fracture healing, since the neuropeptide Substance P has both neurogenic and osteogenic activity. After intramedullary stabilization, an isolated femur fracture was induced in 72 Sprague-Dawley rats. In the NK1-R group, the neurokinin-1-tachykinin receptor for substance P was blocked by a specific antagonist (SR140333) for the first two weeks after fracture induction. The control group only received vehicle. Gene-expression, histology, micro-computed tomography, and biomechanical tests were performed. NK1-receptor blocking suppressed osteocalcin expression at one week, collagen 1A2 expression at one and two weeks and collagen 2A1 expression at 2 weeks after fracture induction. Biomechanical testing revealed a significant reduction in maximal load to failure in the NK1-R group at 6 weeks (69.78 vs. 155.45 N, p = 0.029) and at 3 months (72.50 vs.176.33 N, p = 0.01) of fracture healing. Blocking the NK1-receptor suppresses gene expression in and reduces biomechanical strength of healing bone. Therefore, we assume a potential therapeutic relevance of Substance P in cases of disturbed fracture healing.
Identifiants
pubmed: 31278316
doi: 10.1038/s41598-019-46278-6
pii: 10.1038/s41598-019-46278-6
pmc: PMC6611911
doi:
Substances chimiques
COL2A1 protein, rat
0
Collagen Type I
0
Collagen Type II
0
Neurokinin-1 Receptor Antagonists
0
Piperidines
0
Quinuclidines
0
Osteocalcin
104982-03-8
SR 140333
153050-21-6
Substance P
33507-63-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9744Références
Theranostics. 2016 Jan 01;6(3):328-41
pubmed: 26909109
J Neurosurg Spine. 2016 Apr;24(4):580-5
pubmed: 26682598
Injury. 2015 Apr;46(4):661-5
pubmed: 25682315
Microsc Res Tech. 2002 Jul 15;58(2):85-90
pubmed: 12203707
Clin Orthop Relat Res. 1998 Jun;(351):230-40
pubmed: 9646767
Int J Inflam. 2010 Sep 20;2010:601098
pubmed: 21188216
Acta Orthop Scand. 1992 Dec;63(6):579-86
pubmed: 1471500
Anticancer Res. 2010 Sep;30(9):3345-53
pubmed: 20944107
Matrix Biol. 2014 Sep;38:22-35
pubmed: 25063231
Acta Orthop Scand. 1994 Jun;65(3):299-304
pubmed: 8042482
Bone. 1999 Nov;25(5):545-51
pubmed: 10574574
J Orthop Sci. 2002;7(5):544-8
pubmed: 12355128
Clin Orthop Relat Res. 1995 Feb;(311):247-57
pubmed: 7634582
Crit Care. 2015 Apr 27;19:192
pubmed: 25928056
Neuropeptides. 2007 Oct;41(5):271-83
pubmed: 17655927
J Bone Joint Surg Am. 2010 Mar;92(3):645-53
pubmed: 20194323
Neuropeptides. 2007 Feb;41(1):25-31
pubmed: 17204323
Acta Orthop Scand. 1985 Jun;56(3):233-7
pubmed: 4036573
J Am Assoc Lab Anim Sci. 2010 Mar;49(2):155-9
pubmed: 20353688
Microsc Res Tech. 2002 Jul 15;58(2):61-9
pubmed: 12203704
Bone. 2003 Dec;33(6):927-36
pubmed: 14678852
J Musculoskelet Neuronal Interact. 2008 Apr-Jun;8(2):154-65
pubmed: 18622084
Annu Int Conf IEEE Eng Med Biol Soc. 2016 Aug;2016:2202-2205
pubmed: 28268768
Neuroscience. 2009 Dec 15;164(3):887-95
pubmed: 19761818
Braz J Med Biol Res. 2015 Apr;48(4):299-307
pubmed: 25714881
J Bone Joint Surg Am. 2009 Dec;91(12):2886-95
pubmed: 19952252
J Orthop Trauma. 2006 Jan;20(1):27-38
pubmed: 16424807
J Cell Biochem. 2011 Oct;112(10):2759-72
pubmed: 21748788
Bone. 2009 Aug;45(2):309-20
pubmed: 19379851
J Orthop Res. 1984;2(1):97-101
pubmed: 6491805
J Musculoskelet Neuronal Interact. 2002 Sep;2(5):440-7
pubmed: 15758412
Braz J Biol. 2002 Nov;62(4A):609-14
pubmed: 12659010
Injury. 2005 Mar;36(3):363-8
pubmed: 15710151
J Orthop Res. 2010 Dec;28(12):1643-50
pubmed: 20540103
J Orthop Res. 2006 Oct;24(10):1933-44
pubmed: 16894589
Bone. 2018 Apr;109:22-27
pubmed: 28716552
Peptides. 1997;18(2):323-6
pubmed: 9149307
J Bone Miner Res. 2005 Feb;20(2):257-67
pubmed: 15647820
Endocrinology. 2005 Apr;146(4):1650-73
pubmed: 15618360
Eur J Pharmacol. 1993 Dec 21;250(3):403-13
pubmed: 7509286
J Musculoskelet Neuronal Interact. 2015 Dec;15(4):309-15
pubmed: 26636276
Mediators Inflamm. 2015;2015:204842
pubmed: 25873754